HRP20210919T1 - SPOJEVI KORISNI U INHIBIRANJU ROR-γ-T - Google Patents
SPOJEVI KORISNI U INHIBIRANJU ROR-γ-T Download PDFInfo
- Publication number
- HRP20210919T1 HRP20210919T1 HRP20210919TT HRP20210919T HRP20210919T1 HR P20210919 T1 HRP20210919 T1 HR P20210919T1 HR P20210919T T HRP20210919T T HR P20210919TT HR P20210919 T HRP20210919 T HR P20210919T HR P20210919 T1 HRP20210919 T1 HR P20210919T1
- Authority
- HR
- Croatia
- Prior art keywords
- pharmaceutically acceptable
- acceptable salt
- compound according
- intended
- compound
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title claims 9
- 230000002401 inhibitory effect Effects 0.000 title 1
- 150000003839 salts Chemical class 0.000 claims 8
- 206010002556 Ankylosing Spondylitis Diseases 0.000 claims 1
- 208000025705 Axial Spondyloarthritis Diseases 0.000 claims 1
- GPFKJSWERRLMSX-GOSISDBHSA-N C1(C(F)(F)F)=NC=C([C@@H](C)N2CCC3(C=4SC(=CC=4CC4(CC4)O3)C(=O)NCC3=NC=C(S(=O)(=O)CC)C=C3)CC2)C=N1 Chemical compound C1(C(F)(F)F)=NC=C([C@@H](C)N2CCC3(C=4SC(=CC=4CC4(CC4)O3)C(=O)NCC3=NC=C(S(=O)(=O)CC)C=C3)CC2)C=N1 GPFKJSWERRLMSX-GOSISDBHSA-N 0.000 claims 1
- QIYAHWJLMQLCDQ-GOSISDBHSA-N N-[(5-ethylsulfonylpyridin-2-yl)methyl]-5,5-dimethyl-1'-[(1R)-1-[2-(trifluoromethyl)pyrimidin-5-yl]ethyl]spiro[4H-thieno[2,3-c]pyran-7,4'-piperidine]-2-carboxamide Chemical compound C(C)S(=O)(=O)C=1C=CC(=NC=1)CNC(=O)C1=CC2=C(C3(OC(C2)(C)C)CCN(CC3)[C@H](C)C=2C=NC(=NC=2)C(F)(F)F)S1 QIYAHWJLMQLCDQ-GOSISDBHSA-N 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 201000001263 Psoriatic Arthritis Diseases 0.000 claims 1
- 208000036824 Psoriatic arthropathy Diseases 0.000 claims 1
- 208000006045 Spondylarthropathies Diseases 0.000 claims 1
- 201000002661 Spondylitis Diseases 0.000 claims 1
- 239000012752 auxiliary agent Substances 0.000 claims 1
- 125000002837 carbocyclic group Chemical group 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D495/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D495/20—Spiro-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Claims (8)
1. Spoj formule:
[image]
,
naznačen time što
X is neovisno -N- ili -CH-;
R1 i R2 su oba CH3; ili R1 i R2 se može spojiti zajedno kako bi tvorili tročlani karbociklički prsten;
R3 is -CN ili -CF3;
ili njegova farmaceutski prihvatljiva sol.
2. Spoj u skladu s patentnim zahtjevom 1, naznačen time što je N-{[5-(etilsulfonil)piridin-2-il]metil}-5′,5′-dimetil-1-{(1R)-1-[2-(trifluormetil)pirimidin-5-il]etil}-4′,5′-dihidrospiro[piperidin-4,7′-tieno[2,3-c]piran]-2′-karboksamid:
[image]
,
ili njegova farmaceutski prihvatljiva sol.
3. Spoj u skladu s patentnim zahtjevom 1, naznačen time što je N-{[5-(etilsulfonil)piridin-2-il]metil}-1′′-{(1R)-1-[2-(trifluormetil)pirimidin-5-il]etil}-4′H-dispiro[ciklopropan-1,5′-tieno[2,3-c]piran-7′,4′′-piperidin]-2′-karboksamid:
[image]
,
ili njegova farmaceutski prihvatljiva sol.
4. Farmaceutski pripravak, naznačen time što sadrži spoj u skladu s bilo kojim od patentnih zahtjeva 1-3, ili njegova farmaceutski prihvatljiva sol, u kombinaciji s jednim ili više farmaceutski prihvatljivih nosača, razrjeđivača ili pomoćnih sredstava.
5. Spoj u skladu s bilo kojim od patentnih zahtjeva 1-3, ili njegova farmaceutski prihvatljiva sol, naznačen time što je namijenjen upotrebi u terapiji.
6. Spoj u skladu s bilo kojim od patentnih zahtjeva 1-3, ili njegova farmaceutski prihvatljiva sol, naznačen time što je namijenjen upotrebi u liječenju psorijaze.
7. Spoj u skladu s bilo kojim od patentnih zahtjeva 1-3, ili njegova farmaceutski prihvatljiva sol, naznačen time što je namijenjen upotrebi u liječenju seronegativnih spondilartropatija.
8. Spoj, ili njegova farmaceutski prihvatljiva sol, naznačen time što je namijenjen upotrebi u skladu s patentnim zahtjevom 7 u liječenju aksijalnog spondiloartritisa, ankilozantnog spondilitisa ili psorijatičnog artritisa.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762466110P | 2017-03-02 | 2017-03-02 | |
| PCT/US2018/019907 WO2018160547A1 (en) | 2017-03-02 | 2018-02-27 | Compounds useful for inhibiting ror-gamma-t |
| EP18710280.1A EP3589637B1 (en) | 2017-03-02 | 2018-02-27 | Compounds useful for inhibiting ror-gamma-t |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20210919T1 true HRP20210919T1 (hr) | 2021-09-03 |
Family
ID=61617187
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20210919TT HRP20210919T1 (hr) | 2017-03-02 | 2021-06-09 | SPOJEVI KORISNI U INHIBIRANJU ROR-γ-T |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US10603320B2 (hr) |
| EP (1) | EP3589637B1 (hr) |
| JP (1) | JP6766274B2 (hr) |
| CN (1) | CN110392688B (hr) |
| CY (1) | CY1124258T1 (hr) |
| DK (1) | DK3589637T3 (hr) |
| ES (1) | ES2874132T3 (hr) |
| HR (1) | HRP20210919T1 (hr) |
| LT (1) | LT3589637T (hr) |
| PL (1) | PL3589637T3 (hr) |
| PT (1) | PT3589637T (hr) |
| RS (1) | RS61935B1 (hr) |
| SI (1) | SI3589637T1 (hr) |
| WO (1) | WO2018160547A1 (hr) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108348633B (zh) | 2015-11-06 | 2022-07-08 | 伊西康公司 | 压实止血纤维素聚集体 |
| CN110337440B (zh) * | 2017-03-02 | 2021-08-03 | 伊莱利利公司 | 可用于抑制ROR-γ-t的化合物 |
| WO2022122740A1 (en) | 2020-12-07 | 2022-06-16 | Diaccurate | Ror-gamma inhibitors for the treatment of ror-gamma-dependent cancer |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MXPA05000729A (es) * | 2002-07-17 | 2005-04-08 | Warner Lambert Co | Combinacion de un inhibidor alosterico de metaloproteinasa-13 de matriz con celecoxib o valdecoxib. |
| UA107943C2 (en) * | 2009-11-16 | 2015-03-10 | Lilly Co Eli | Compounds of spiropiperidines as antagonists of the orl-1 receptors |
| SI2501704T1 (sl) * | 2009-11-16 | 2013-11-29 | Eli Lilly Company | Spojine spiropiperidina kot antagonisti oral-1 receptorja |
| TWI582096B (zh) * | 2011-12-06 | 2017-05-11 | 美國禮來大藥廠 | 用於酒精依賴及濫用處理之４',５'－二氫螺［哌啶－４,７'－噻吩并[２，３－c]哌喃］化合物 |
| WO2014179564A1 (en) | 2013-05-01 | 2014-11-06 | Vitae Pharmaceuticals, Inc. | Thiazalopyrrolidine inhibitors of ror-gamma |
| JP6192836B2 (ja) * | 2013-07-30 | 2017-09-06 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｒｏｒｃモジュレーターとしてのアザインドール化合物 |
| WO2015101928A1 (en) | 2013-12-31 | 2015-07-09 | Aurigene Discovery Technologies Limited | Fused thiophene and thiazole derivatives as ror gamma modulators |
| MX2016009621A (es) * | 2014-01-24 | 2016-11-17 | Abbvie Inc | Derivados de fur0-3-carboxamida y metodos de uso. |
| AR105821A1 (es) * | 2015-09-09 | 2017-11-15 | Lilly Co Eli | COMPUESTOS ÚTILES PARA INHIBIR ROR-g-T |
-
2018
- 2018-02-27 PT PT187102801T patent/PT3589637T/pt unknown
- 2018-02-27 SI SI201830270T patent/SI3589637T1/sl unknown
- 2018-02-27 EP EP18710280.1A patent/EP3589637B1/en active Active
- 2018-02-27 LT LTEP18710280.1T patent/LT3589637T/lt unknown
- 2018-02-27 WO PCT/US2018/019907 patent/WO2018160547A1/en unknown
- 2018-02-27 CN CN201880015347.XA patent/CN110392688B/zh not_active Expired - Fee Related
- 2018-02-27 JP JP2019547671A patent/JP6766274B2/ja not_active Expired - Fee Related
- 2018-02-27 PL PL18710280T patent/PL3589637T3/pl unknown
- 2018-02-27 RS RS20210699A patent/RS61935B1/sr unknown
- 2018-02-27 DK DK18710280.1T patent/DK3589637T3/da active
- 2018-02-27 ES ES18710280T patent/ES2874132T3/es active Active
- 2018-02-27 US US16/482,602 patent/US10603320B2/en not_active Expired - Fee Related
-
2021
- 2021-06-09 HR HRP20210919TT patent/HRP20210919T1/hr unknown
- 2021-06-10 CY CY20211100517T patent/CY1124258T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ES2874132T3 (es) | 2021-11-04 |
| EP3589637A1 (en) | 2020-01-08 |
| LT3589637T (lt) | 2021-06-25 |
| CN110392688B (zh) | 2021-09-10 |
| US10603320B2 (en) | 2020-03-31 |
| JP2020509054A (ja) | 2020-03-26 |
| JP6766274B2 (ja) | 2020-10-07 |
| CY1124258T1 (el) | 2022-07-22 |
| SI3589637T1 (sl) | 2021-08-31 |
| RS61935B1 (sr) | 2021-07-30 |
| US20200009139A1 (en) | 2020-01-09 |
| PT3589637T (pt) | 2021-06-02 |
| DK3589637T3 (da) | 2021-06-14 |
| PL3589637T3 (pl) | 2021-10-04 |
| EP3589637B1 (en) | 2021-04-14 |
| WO2018160547A1 (en) | 2018-09-07 |
| CN110392688A (zh) | 2019-10-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20210919T1 (hr) | SPOJEVI KORISNI U INHIBIRANJU ROR-γ-T | |
| HRP20191268T1 (hr) | Derivati tieno[2,3-c]pirol-4-ona kao inhibitori erk | |
| HRP20180483T1 (hr) | Spoj kinolona | |
| PE20181093A1 (es) | Compuestos heterociclicos y usos de los mismos | |
| PE20130602A1 (es) | Derivados de 6-cicloalquil-1,5-dihidro-pirazolo(3,4-d)pirimidin-4-onas y su uso como inhibidores de pde9a | |
| PE20181198A1 (es) | Derivados de heterociclos biciclicos condensados como agentes de control de plagas | |
| PE20151749A1 (es) | Compuestos amida para el tratamiento del vih | |
| JP2016536363A5 (hr) | ||
| CY1120325T1 (el) | Τρικυκλικες ετεροκυκλικες ενωσεις ως αναστολεις φωσφοϊνοσιτιδιου 3-κινασης | |
| JP2017537940A5 (hr) | ||
| HRP20201094T1 (hr) | IMIDAZO[1,2-a]PIRIDINI, NAMIJENJENI LIJEČENJU ILI SPRJEČAVANJU HIPERURIKEMIJE ILI GIHTA | |
| PE20211472A1 (es) | Derivados de 2-(feniloxi o feniltio)pirimidina como herbicidas | |
| BR112014027143A2 (pt) | pirrolobenzodiazepinas | |
| HRP20171515T1 (hr) | Spojevi fenoksietilpiperidina | |
| JP2016506962A5 (hr) | ||
| SI2978752T1 (en) | 6- (5-Hydroxy-1H-pyrazol-1-yl) nicotinamide derivatives and their use as inhibitors of PHD | |
| JP2016506960A5 (hr) | ||
| EA201592252A1 (ru) | 6,7-ДИГИДРОПИРАЗОЛО[1,5-a]ПИРАЗИН-4(5H)-ОНОВЫЕ СОЕДИНЕНИЯ И ИХ ПРИМЕНЕНИЕ В КАЧЕСТВЕ ОТРИЦАТЕЛЬНЫХ АЛЛОСТЕРИЧЕСКИХ МОДУЛЯТОРОВ РЕЦЕПТОРОВ MGLUR2 | |
| HRP20192235T1 (hr) | SPOJEVI KORISNI ZA INHIBITIRANJE ROR-γ-T | |
| AR093937A1 (es) | Compuestos quimicos | |
| EA201591804A1 (ru) | Производные 2-((4-амино-3-(3-фтор-5-гидроксифенил)-1h-пиразоло[3,4-d]пиримидин-1-ил)метил)-3-(2-(трифторметил)бензил)хиназолин-4(3h)-она и их применение в качестве ингибиторов фосфоинозитид-3-киназы | |
| RU2015155585A (ru) | 4-алкинилимидазольное производное и лекарственное средство, включающее такое производное в качестве активного ингредиента | |
| AR081725A1 (es) | Derivados de oxadiazol, proceso de preparacion de los mismos, composicion farmaceutica que los contienen y su uso en el tratamiento del cancer | |
| EA201992771A1 (ru) | Ингибитор поверхностного антигена вируса гепатита b | |
| HRP20201522T1 (hr) | Heteroaromatski nmda receptor modulatori i njihove uporabe |